You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 2, 2024

DIHYDROERGOTAMINE MESYLATE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for dihydroergotamine mesylate and what is the scope of patent protection?

Dihydroergotamine mesylate is the generic ingredient in five branded drugs marketed by Bausch, Gland Pharma Ltd, Hikma, Hikma Pharms, Padagis Us, Provepharm Sas, Sagent Pharms Inc, Amneal, Cipla, Rubicon, Jn Bidco, and Novartis, and is included in fourteen NDAs. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Dihydroergotamine mesylate has sixty-four patent family members in sixteen countries.

There are six drug master file entries for dihydroergotamine mesylate. Ten suppliers are listed for this compound.

Summary for DIHYDROERGOTAMINE MESYLATE
Drug Prices for DIHYDROERGOTAMINE MESYLATE

See drug prices for DIHYDROERGOTAMINE MESYLATE

Recent Clinical Trials for DIHYDROERGOTAMINE MESYLATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Ache Laboratorios Farmaceuticos S.A.Phase 3
Xijing HospitalPhase 2/Phase 3
Satsuma Pharmaceuticals, Inc.Phase 3

See all DIHYDROERGOTAMINE MESYLATE clinical trials

Pharmacology for DIHYDROERGOTAMINE MESYLATE
Medical Subject Heading (MeSH) Categories for DIHYDROERGOTAMINE MESYLATE

US Patents and Regulatory Information for DIHYDROERGOTAMINE MESYLATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hikma DIHYDROERGOTAMINE MESYLATE dihydroergotamine mesylate INJECTABLE;INJECTION 040453-001 Jun 9, 2003 AP RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Novartis EMBOLEX dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride INJECTABLE;INJECTION 018885-002 Nov 30, 1984 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Cipla DIHYDROERGOTAMINE MESYLATE dihydroergotamine mesylate SPRAY, METERED;NASAL 212907-001 May 20, 2020 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for DIHYDROERGOTAMINE MESYLATE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch MIGRANAL dihydroergotamine mesylate SPRAY, METERED;NASAL 020148-001 Dec 8, 1997 ⤷  Try a Trial ⤷  Try a Trial
Bausch MIGRANAL dihydroergotamine mesylate SPRAY, METERED;NASAL 020148-001 Dec 8, 1997 ⤷  Try a Trial ⤷  Try a Trial
Bausch MIGRANAL dihydroergotamine mesylate SPRAY, METERED;NASAL 020148-001 Dec 8, 1997 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.